Analysis of baseline RCC tumors revealed a cluster of correlated genes in T cell activation, IFNg-signaling, and antigen presentation pathways; this cluster was not significantly associated with tumor response to CPI-444 monotherapy or combination. This evidence concerns the gene IFNG and neoplasm.